Cancer Research UK, KWF Dutch Cancer Society enter partnership to bring drugs into clinical development

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Guest Editorial

New drugs don’t appear out of thin air

As a physician-scientist who has navigated drug development from lab bench to bedside to executive boardroom, I want to touch upon a subject that is near and dear to my heart: the state of American science—a linchpin of our healthcare system and national competitiveness.

March 14, 2025

Vol.51 No.10

By William Pao

Capitol Hill

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown.

January 10, 2025

Vol.51 No.01

By Claire Marie Porter

Clinical Roundup

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

Cancer Research UK, KWF Dutch Cancer Society enter partnership to bring drugs into clinical development

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

FDA approves prostate cancer imaging agent Gozellix

New drugs don’t appear out of thin air

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

Renew today!

Subscriber content

Never miss an issue!

Login

Cancer Research UK, KWF Dutch Cancer Society enter partnership to bring drugs into clinical development

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

FDA approves prostate cancer imaging agent Gozellix

New drugs don’t appear out of thin air

Pediatric cancer research cut from spending legislation at last minuteRepublicans quietly removed hard-won pediatric cancer bills

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills